KC Herold, AG Montag, FW Fitch - Diabetes, 1987 - Am Diabetes Assoc The importance of T-lymphocytes in the induction of insulitis and hyperglycemia in certain strains
of mice treated with multiple subdiabetogenic doses of streptozocin has been a matter of
controversy. To understand the role of T-lymphocytes, we treated thymectomized BALB/c ... Cited by 39 - Related articles - All 4 versions
- ►jimmunol.org JA Smith, Q Tang, JA Bluestone - The Journal of Immunology, 1998 - Am Assoc Immnol Anti-CD3 mAbs with low FcR affinity prolong graft survival in the absence of the cytokine-mediated
toxicity observed with conventional anti-CD3 treatment. Previous studies have shown that
FcR-nonbinding anti-CD3 mAbs suppress immune responses, at least in part, by ... Cited by 65 - Related articles - BL Direct - All 3 versions
- ►nih.gov KC Herold, JB Burton, F Francois, E … - Journal of clinical …, 2003 - Am Soc Clin Investig Dimeric Fc receptor (FcR) nonbinding anti-CD3 antibodies have been developed to minimize
toxicities associated with classical anti-CD3 monoclonal antibodies (eg, OKT3). Studies with
murine analogs of non-FcR–binding antibodies have shown reduced mitogenicity ... Cited by 120 - Related articles - BL Direct - All 8 versions
ES Woodle, D Xu, RA Zivin, J Auger, J Charette, R O' … - Transplantation, 1999 - journals.lww.com Skip Navigation Links Home > September 15, 1999 - Volume 68 - Issue 5 > PHASE I TRIAL OF
A HUMANIZED, Fc RECEPTOR NONBINDING OKT3 AN... ... Woodle, E. Steve; Xu, Danlin;
Zivin, Robert A.; Auger, Julie; Charette, Jane; O'Laughlin, Rita; Peace, Donna; Jolliffe, ... Cited by 103 - Related articles - All 4 versions
L Chatenoud, J Primo, JF Bach - The Journal of Immunology, 1997 - Am Assoc Immnol Page 1. CD3 Antibody-Induced Dominant Self Tolerance in Overtly Diabetic NOD Mice' Lucienne
Chatenoud,2 Jacqueline Primo, and Jean-Frangois Bach Low doses of the CD3 mAb 145 2C11
restored self tolerance to cell Ags in adult overtly diabetic NOD mice. Within 2 to 4 ... Cited by 200 - Related articles - BL Direct - All 4 versions
L Chatenoud, E Thervet, J Primo, JF … - Proc Natl Acad Sci …, 1994 - National Acad Sciences Institut National de la Sant6 et de la Recherche M6dicale U 25, H6pital Necker, 161 Rue de
Sevres, 75015 Paris, France Communicated by N. Le Douarin, August 23, 1993 ... ABSTRACT
Anti-CD3 monoclonal antibodies suppress immune responses by transient T-cell ... Cited by 295 - Related articles - BL Direct - All 10 versions
- ►rupress.org JA Smith, JY Tso, MR Clark, MS Cole, JA … - Journal of Experimental …, 1997 - jem.rupress.org Anti-CD3 monoclonal antibodies (mAbs) are potent immunosuppressive agents used in clinical
transplantation. However, the activation-related adverse side effects associated with these mAbs
have prompted the development of less toxic nonmitogenic anti-CD3 mAb therapies. At ... Cited by 118 - Related articles - BL Direct - All 5 versions
DA Vallera, SF Carroll, S Brief, BR Blazar - Diabetes, 1992 - Am Diabetes Assoc Autoimmune diabetes was induced with an established model in which 3 daily injections of 95
mg/kg body wt/day streptozocin (STZ) and 2 x 10(4) U interferon-gamma (IFN-gamma) were
administered to C57BL/6 mice. Diabetes onset was accompanied by precipitous ... Cited by 19 - Related articles - All 4 versions
D Xu, ML Alegre, SS Varga, AL Rothermel, AM Collins, … - Cellular Immunology, 2000 - Elsevier Orthoclone OKT 3 (mOKT3) is a highly effective agent for the reversal of steroid-resistant renal
allograft rejection. However, its wider use has been limited by the development of a human
anti-mouse antibody response (HAMA) and by the “cytokine release syndrome” (CRS). ... Cited by 55 - Related articles - BL Direct - All 5 versions
